Has Lakshmikanth Katragadda, MD received payments from drug or device companies?

Yes. Drug and device makers reported $212,168 in general payments to Lakshmikanth Katragadda, MD across 471 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lakshmikanth Katragadda, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lakshmikanth Katragadda, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lakshmikanth Katragadda, MD

Hematology & Oncology · Huntsville, ALNPI 1336303940

Payments from drug & device makers

$212,168in general payments, 2019–2025

Across 471 payments — averaging $450.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Beigene, Ltd.$177K
Beone Medicines USA, Inc.$20K
Beigene USA, Inc.$4K
AstraZeneca$2K
Sanofi$744
Pfizer$598
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Beigene, Ltd.	6	$176,600
Beone Medicines USA, Inc.	12	$20,223
Beigene USA, Inc.	6	$3,951
AstraZeneca(2 entities)	29	$1,946
Sanofi	17	$744
Pfizer	31	$598
E.r. Squibb & Sons, L.L.C.	41	$597
Novartis	25	$512
Karyopharm Therapeutics Inc.	10	$474
Seagen Inc.	21	$447
Welch Allyn	1	$432
Eisai Inc.	24	$397
Bristol Myers Squibb	19	$356
Daiichi Sankyo Inc.	14	$293
GSK	10	$292
Incyte Corporation	17	$277
Johnson & Johnson	16	$270
Pharmacyclics LLC, An Abbvie Company	16	$267
Merck	15	$247
Regeneron Healthcare Solutions, Inc.	7	$228
Gilead(2 entities)	12	$214
Amgen	11	$169
Blueprint Medicines Corporation	3	$163
Secura Bio, Inc.	2	$162
Bayer	7	$133
Rigel Pharmaceuticals, Inc.	2	$129
Array Biopharma Inc	7	$127
Novo Nordisk	1	$123
Stemline Therapeutics Inc.	5	$119
Puma Biotechnology, Inc.	7	$119
AbbVie	2	$117
CTI Biopharma Corp.	5	$116
Sobi, Inc	4	$107
Boehringer Ingelheim	6	$106
Takeda Pharmaceuticals U.S.A., Inc.	4	$98
AVEO Pharmaceuticals, Inc.	4	$74
Springworks Therapeutics, Inc.	4	$71
Genentech USA, Inc.	3	$68
Pharmaessentia USA Corporation	3	$62
Adaptive Biotechnologies Corporation	2	$56
Pharmacosmos Therapeutics Inc.	3	$52
Agios Pharmaceuticals, Inc.	3	$48
Iovance Biotherapeutics, Inc.	2	$41
Tesaro, Inc.	2	$38
Taiho Oncology, Inc.	2	$36
G1 Therapeutics, Inc.	2	$32
Deciphera Pharmaceuticals Inc.	2	$32
Shield Therapeutics Inc	1	$30
Ipsen Biopharmaceuticals, Inc	2	$28
Tempus AI, Inc	1	$24
Lilly USA, LLC	2	$23
Immunocore Limited	1	$22
Jazz Pharmaceuticals Inc.	1	$22
Myovant Sciences Inc.	1	$20
Heron Therapeutics, Inc.	1	$20
Tolmar, Inc.	1	$20
Exelixis Inc.	1	$19
ADC Therapeutics America, Inc.	1	$17
Recordati_rare_diseases_inc.	1	$17
EUSA Pharma (US) LLC	1	$16

How this compares

$212,168 in reported general payments places this provider in the 75th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$7,083,030

Medicare patients

1,028

Services billed

216,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Huntsville

Daniel SchreederHuntsville$117K
Jorge Diaz CastroHuntsville$75K
Surrinder DangHuntsville$74K
Brian MathewsHuntsville$71K
Luciano CostaBirmingham$32.8M
Amitkumar MehtaBirmingham$18.6M
Erica Stringer-ReasorBirmingham$18.1M
Susan BalBirmingham$11.3M
Pankit VachhaniBirmingham$7.9M
Mehmet AkceBirmingham$5.4M

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →